坐骨神經痛治療市場規模、佔有率和成長分析（按類型、藥物類別、分銷管道和地區）- 產業預測 2025-2032

2023 年全球坐骨神經痛治療市場規模價值 7.3474 億美元，預計將從 2024 年的 7.6486 億美元成長到 2032 年的 10.5485 億美元，預測期內（2025-2032 年）的複合年成長率為 4.1%。

根據市場洞察，坐骨神經痛病例呈現上升趨勢，主要是由於久坐的生活方式、肥胖率上升和人口老化。此症狀表現為沿著坐骨神經的放射性疼痛，並常與椎間盤突出、骨刺或脊椎狹窄有關。診斷技術的進步使得坐骨神經痛的辨識更加準確，導致報告病例數急劇增加。研究表明，大約40％的人患有坐骨神經痛，40至50歲之間的發病率最高，男性比女性更常見。隨著對坐骨神經痛的認知和診斷的提高，解決坐骨神經痛的根本原因對於控制其對不斷成長的患者群體的影響至關重要。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

坐骨神經痛治療市場規模（按類型）

• 市場概況
• 急性
• 慢性的
• 其他

坐骨神經痛治療市場規模（依藥物類別）

• 市場概況
• 非類固醇消炎劑(NSAID)
• 皮質類固醇
• 抗憂鬱症
• 其他

坐骨神經痛治療市場規模（依分銷管道）

• 市場概況
• 醫院藥房
• 零售及網路藥局

坐骨神經痛治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• Johnson & Johnson（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Endo Pharmaceuticals（United States）
• Stryker Corporation（United States）
• Medtronic PLC（Ireland）
• Abbott Laboratories（United States）
• Bayer AG（Germany）
• Sanofi SA（France）
• AstraZeneca PLC（United Kingdom）
• Amneal Pharmaceuticals, Inc.（United States）
• Aurobindo Pharma Limited（India）
• Sun Pharmaceutical Industries Ltd.（India）
• Sorrento Therapeutics, Inc.（United States）
• Alkem Laboratories Ltd.（India）
• Eliem Therapeutics, Inc.（United States）
• Sinfonia Biotherapeutics（United States）
• Omega Laser Systems Ltd.（United Kingdom）

結論和建議

Global Sciatica Treatment Market size was valued at USD 734.74 million in 2023 and is poised to grow from USD 764.86 million in 2024 to USD 1054.85 million by 2032, growing at a CAGR of 4.1% during the forecast period (2025-2032).

Market insights indicate a rising trend in sciatica cases, largely influenced by sedentary lifestyles, increasing obesity rates, and an aging demographic. This condition manifests as pain radiating along the sciatic nerve, often related to herniated disks, bone spurs, or spinal stenosis. Advancements in diagnostic technologies have further improved the identification of sciatica, resulting in a surge of reported cases. Research shows that around 40% of individuals will experience sciatica at some point, with the highest frequency observed in those aged 40 to 50, and a greater prevalence in men compared to women. As awareness and diagnosis improve, addressing sciatica's underlying causes will be essential for managing its impact on the growing patient population.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sciatica Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sciatica Treatment Market Segments Analysis

Global Sciatica Treatment Market is segmented by Type, Drug Class, Distribution Channel and region. Based on Type, the market is segmented into Acute, Chronic and Others. Based on Drug Class, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Antidepressants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies and Retail & Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sciatica Treatment Market

The global Sciatica Treatment market is significantly influenced by the high prevalence of sciatica, a condition affecting 10-40% of the population, particularly among older individuals, with a lifetime occurrence rate of up to 43%. This rising incidence of both chronic and acute cases, especially in adults aged 60 and above, where rates soar to 19.2%, drives the demand for effective treatments. While surgical options like microdiscectomy or spinal fusion are available, their high costs present accessibility challenges, particularly in low- and middle-income nations with limited healthcare resources. Emerging treatments, such as stem cell therapy, though promising, may also lack adequate insurance coverage, further complicating patient access to necessary care.

Restraints in the Global Sciatica Treatment Market

The Global Sciatica Treatment market faces significant restraints primarily due to the high costs associated with surgical interventions, such as microdiscectomy and spinal fusion, which are commonly recommended for sciatica relief. Furthermore, emerging therapies like stem cell treatment, despite their potential benefits, also come with increased expenses, and there is uncertainty regarding insurance coverage for these advanced procedures. These financial burdens create substantial barriers, restricting access to various treatment options, especially for patients in low- and middle-income nations where healthcare resources are limited. Ultimately, the economic constraints significantly hinder the ability to seek adequate sciatica care for many individuals.

Market Trends of the Global Sciatica Treatment Market

The Global Sciatica Treatment Market is experiencing significant growth, driven largely by advancements in diagnostic imaging technologies such as MRI and CT scans. These innovations have transformed the identification of sciatica's underlying causes, allowing for faster and more accurate diagnoses, which facilitate timely interventions. Early detection is essential in averting the progression from acute sciatica to chronic, debilitating conditions. Enhanced diagnostic precision empowers healthcare providers to deliver effective treatments promptly, improving patient outcomes and reducing the risk of disability. Additionally, the increasing prevalence of sciatica cases is further propelling market expansion, underscoring the importance of innovative solutions in managing this condition.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Sciatica Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Acute
• Chronic
• Others

Global Sciatica Treatment Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• Antidepressants
• Others

Global Sciatica Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail & Online Pharmacies

Global Sciatica Treatment Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkem Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eliem Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinfonia Biotherapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omega Laser Systems Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations